David Protein CEO Peter Rahal previews new bar, targets $300M+ in 2026 revenue, and launches in Target and Walmart in January
Nov 28, 2025 with Peter Rahal
Key Points
- David Protein targets north of $300 million in 2026 revenue by deliberately throttling demand through Q4 2024 to build safety stock ahead of Target and Walmart launches in January.
- CEO Peter Rahal plans a house-of-brands model modeled on Mars, with new products launching beyond 2025 only if measurably 30% better than existing market alternatives.
- David eschews discounts and celebrity influencer marketing in favor of Meta ads, health podcasts like Huberman Lab, and physical sampling to protect brand equity.
Summary
Peter Rahal, founder and CEO of David Protein, is targeting north of $300 million in 2026 revenue, up from a business that is just 15 months old. The company is deliberately throttling demand through Q4 2024 to build safety stock, with supply chain preparation for the 2026 ramp underway since August. Rahal frames the deliberate slowdown as risk management ahead of a major retail expansion.
Target and Walmart launches are set for January 2025, marking David's first significant brick-and-mortar presence. Rahal describes this as a "huge lift" and expects the majority of major retail distribution to be secured throughout 2026. A new bar product — previewed on camera but not yet named — also launches in January under the David brand.
The business is seasonal in a counterintuitive direction. Q4 is slow, with December-to-January sales jumping roughly 50% month over month as New Year health resolutions kick in. On Black Friday, sales run only about 20% below a typical day despite no promotional participation, which Rahal notes as better than expected given the competitive noise of the period. David's promotional philosophy avoids discounts entirely, substituting a buy-four-get-one-free mechanic to protect brand equity and perceived value.
The team currently sits at roughly 80 people, with a target productivity benchmark of $2 million revenue per head. At $300 million-plus, that implies a headcount ceiling just north of 150, signaling continued lean operations.
On the growth side, Meta ads and health-focused podcasts — specifically calling out Huberman Lab — are the primary paid channels. Rahal is skeptical of traditional influencer marketing, arguing that celebrity posts that visibly moved RXBAR sales in 2016 no longer produce the same effect due to audience fatigue and the professionalization of influencer pricing. Physical sampling at scale remains a core tactic.
Rahal's long-term model is a house of brands, with Mars cited as the explicit reference company. He is planting seeds now for additional brands to launch beyond 2025, applying a consistent product development filter: any new product must be measurably 30% better than the existing market, not differentiated primarily on branding. He views food and fashion as structurally similar in their perpetual need for novelty, which he sees as sustaining long-term opportunity.
On pricing and addressable market, Rahal is candid that David's current price point limits its TAM. He argues the portfolio needs to get "less expensive and crunchier" over time to access mass-market volume, pointing to the $10-for-10 promotional tier as the threshold required to reach $1 billion in revenue. An IPO is something Rahal describes as a "notch on the belt" but frames as a decision he would approach objectively rather than as a goal in itself.
Portfolio investment activity is largely on the back burner while Rahal stays focused on David. One standout he flags is Willy's, a THC beverage brand that pivoted from the June Shine kombucha business, which he says is posting strong numbers against the macro tailwind of consumers seeking alcohol alternatives.